 OSAKA, Japan CAMBRIDGE, Mass.BUSINESS WIRETakeda TSE:4502NYSE:TAK today announced that it has entered into an exclusive licensing agreement with HUTCHMED China Limited NasdaqAIM: HCM, HKEX: 13 and its subsidiary HUTCHMED Limited, for the further development and commercialization of fruquintinib outside of mainland China, Hong Kong and Macau. Approved in China in 2018, fruquintinib is a ...... 